Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study

Area of Science:

• Hematology
• Gene Therapy
• Molecular Biology

Background:

• Sickle cell disease (SCD) is an inherited blood disorder.
• Gene therapy offers a potential treatment, especially for patients without bone marrow donors.
• Developing efficient lentiviral vectors for high-level, long-term gene expression is crucial.

Purpose of the Study:

• To compare the efficacy of two lentiviral vectors (Lenti/βAS3-FB and Globe-AS3) for sickle cell disease gene therapy.
• To evaluate vector performance in vitro using patient-derived CD34+ cells and in vivo using mouse models.
• To determine the optimal vector for future clinical applications in SCD.

Main Methods:

• Direct comparison of two lentiviral vectors (Lenti/βAS3-FB and Globe-AS3) carrying an anti-sickling β-globin transgene (AS3).
• In vitro studies using human bone marrow CD34+ cells from SCD patients and erythroid differentiation models.
• In vivo studies using NOD SCID gamma and sickle mouse models to assess transduction efficiency, gene expression, and phenotypic correction.

Main Results:

• Minor differences observed in vitro, with Globe-AS3 showing a 2.4-fold higher vector copy number in CD34+ cells.
• No significant differences in the overall correction of the sickle cell disease phenotype were observed in the in vivo mouse models.
• Both vectors demonstrated potential for gene therapy applications in SCD.

Conclusions:

• Both Lenti/βAS3-FB and Globe-AS3 vectors are effective in correcting the sickle cell phenotype in vivo.
• The choice between vectors may depend on specific in vitro efficiency metrics, but in vivo correction was comparable.
• This comprehensive analysis aids in selecting the optimal lentiviral vector for sickle cell disease gene therapy.